Finn Sellebjerg

List of Publications by Year
in descending order

113 papers	6,593 citations	147566 31 h-index	69108 77 g-index
123 all docs	123 docs citations	123 times ranked	11093 citing authors

#	Article	IF	Citations
1	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature, 2011, 476, 214-219.	13.7	2,400
2	Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nature Genetics, 2013, 45, 1353-1360.	9.4	1,213
3	Systemic Inflammation in Progressive Multiple Sclerosis Involves Follicular T-Helper, Th17- and Activated B-Cells and Correlates with Progression. PLoS ONE, 2013, 8, e57820.	1.1	213
4	FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS. Nature Medicine, 2014, 20, 272-282.	15.2	141
5	Natalizumab in progressive MS. Neurology, 2014, 82, 1499-1507.	1.5	110
6	Serum neurofilament light as a biomarker in progressive multiple sclerosis. Neurology, 2020, 95, 436-444.	1.5	100
7	Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis. JAMA Neurology, 2021, 78, 1197.	4.5	90
8	Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark. Neurology, 2018, 91, e2265-e2275.	1.5	84
9	Initial high-efficacy disease-modifying therapy in multiple sclerosis. Neurology, 2020, 95, e1041-e1051.	1.5	83
10	Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis. Brain, 2019, 142, 120-132.	3.7	81
11	CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 877-884.	1.4	75
12	Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e191.	3.1	69
13	Vitamin D supplementation reduces relapse rate in relapsing-remitting multiple sclerosis patients treated with natalizumab. Multiple Sclerosis and Related Disorders, 2016, 10, 169-173.	0.9	68
14	Effect of Natalizumab on Circulating CD4+ T-Cells in Multiple Sclerosis. PLoS ONE, 2012, 7, e47578.	1.1	59
15	The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history. Brain, 2020, 143, 2637-2652.	3.7	56
16	Disentangling white-matter damage from physiological fibre orientation dispersion in multiple sclerosis. Brain Communications, 2020, 2, fcaa077.	1.5	55
17	Relationship between Cerebrospinal Fluid Biomarkers for Inflammation, Demyelination and Neurodegeneration in Acute Optic Neuritis. PLoS ONE, 2013, 8, e77163.	1.1	55
18	Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. Brain, 2015, 138, 632-643.	3.7	54

#	Article	IF	Citations
19	Pulsed immune reconstitution therapy in multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641983691.	1.5	54
20	Selected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e287.	3.1	53
21	Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis. CNS Drugs, 2020, 34, 269-280.	2.7	49
22	Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1444-1451.	1.4	47
23	The interaction between smoking and HLA genes in multiple sclerosis: replication and refinement. European Journal of Epidemiology, 2017, 32, 909-919.	2.5	45
24	Serum Short-Chain Fatty Acids and Associations With Inflammation in Newly Diagnosed Patients With Multiple Sclerosis and Healthy Controls. Frontiers in Immunology, 2021, 12, 661493.	2.2	43
25	A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod. Multiple Sclerosis Journal, 2017, 23, 234-241.	1.4	38
26	High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial. Multiple Sclerosis Journal, 2017, 23, 675-685.	1.4	38
27	Smoking affects the interferon beta treatment response in multiple sclerosis. Neurology, 2018, 90, e593-e600.	1.5	38
28	Comparative effectiveness of teriflunomide and dimethyl fumarate. Neurology, 2019, 92, e1811-e1820.	1.5	36
29	Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden. Annals of the Rheumatic Diseases, 2020, 79, 566-572.	0.5	36
30	Incidence of pediatric neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease in Denmark 2008â€'2018: A nationwide, population-based cohort study. Multiple Sclerosis and Related Disorders, 2019, 33, 162-167.	0.9	35
31	Defining active progressive multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 1727-1735.	1.4	34
32	CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage. Multiple Sclerosis Journal, 2019, 25, 937-946.	1.4	32
33	Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. PLoS Medicine, 2020, 17, e1003348.	3.9	31
34	GPR15+ T cells are Th17 like, increased in smokers and associated with multiple sclerosis. Journal of Autoimmunity, 2019, 97, 114-121.	3.0	30
35	Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2016, 9, 31-43.	1.5	29
36	Systemic frequencies of T helper 1 and T helper 17 cells in patients with age-related macular degeneration: A case-control study. Scientific Reports, 2017, 7, 605.	1.6	29

#	Article	IF	Citations
37	Association between age at onset of multiple sclerosis and vitamin D levelâ€“related factors. Neurology, 2016, 86, 88-93.	1.5	28
38	Orthologous proteins of experimental de- and remyelination are differentially regulated in the CSF proteome of multiple sclerosis subtypes. PLoS ONE, 2018, 13, e0202530.	1.1	28
39	Neutrophilâ€toâ€lymphocyte ratio and CRP as biomarkers in multiple sclerosis: A systematic review. Acta Neurologica Scandinavica, 2021, 143, 577-586.	1.0	27
40	Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1298-1305.	1.4	24
41	Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases. Multiple Sclerosis and Related Disorders, 2021, 52, 102988.	0.9	24
42	Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 926-934.	1.4	23
43	Relationship between Multiple Sclerosis-Associated IL2RA Risk Allele Variants and Circulating T Cell Phenotypes in Healthy Genotype-Selected Controls. Cells, 2019, 8, 634.	1.8	22
44	Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. Journal of Neuroimmunology, 2019, 326, 19-27.	1.1	22
45	Characterization of naÃ¯ve, memory and effector T cells in progressive multiple sclerosis. Journal of Neuroimmunology, 2017, 310, 17-25.	1.1	20
46	Endogenous Interferon-Î²-Inducible Gene Expression and Interferon-Î²-Treatment Are Associated with Reduced T Cell Responses to Myelin Basic Protein in Multiple Sclerosis. PLoS ONE, 2015, 10, e0118830.	1.1	18
47	Genetic and environmental determinants of 25-hydroxyvitamin D levels in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1414-1422.	1.4	18
48	B cells from patients with multiple sclerosis have a pathogenic phenotype and increased LTÎ± and TGFÎ²1 response. Journal of Neuroimmunology, 2018, 324, 157-164.	1.1	18
49	Dimethyl fumarate therapy suppresses B cell responses and follicular helper T cells in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1289-1297.	1.4	18
50	IL-6, IL-12, and IL-23 STAT-Pathway Genetic Risk and Responsiveness of Lymphocytes in Patients with Multiple Sclerosis. Cells, 2019, 8, 285.	1.8	18
51	Dimethyl fumarate therapy reduces memory T cells and the CNS migration potential in patients with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 37, 101451.	0.9	18
52	Human pegivirus detected in a patient with severe encephalitis using a metagenomic pan-virus array. Journal of Clinical Virology, 2016, 77, 5-8.	1.6	17
53	Smoking reduces circulating CD26hiCD161hi MAIT cells in healthy individuals and patients with multiple sclerosis. Journal of Leukocyte Biology, 2017, 101, 1211-1220.	1.5	17
54	Increased cerebrospinal fluid chitinase 3-like 1 and neurofilament light chain in pediatric acquired demyelinating syndromes. Multiple Sclerosis and Related Disorders, 2018, 24, 175-183.	0.9	17

#	Article	IF	Citations
55	Ofatumumab Modulates Inflammatory T Cell Responses and Migratory Potential in Patients With Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	17
56	Extended dosing of monoclonal antibodies in multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 2001-2009.	1.4	16
57	Neurofilament in CSFâ€"A biomarker of disease activity and long-term prognosis in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1112-1113.	1.4	15
58	Dimethyl Fumarate Treatment in Patients With Primary Progressive Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	15
59	Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	15
60	Endogenous and Recombinant Type I Interferons and Disease Activity in Multiple Sclerosis. PLoS ONE, 2012, 7, e35927.	1.1	14
61	Alcohol consumption in adolescence is associated with a lower risk of multiple sclerosis in a Danish cohort. Multiple Sclerosis Journal, 2019, 25, 1572-1579.	1.4	14
62	Structural and cognitive correlates of fatigue in progressive multiple sclerosis. Neurological Research, 2019, 41, 168-176.	0.6	14
63	Genetic burden of MS risk variants distinguish patients from healthy individuals but are not associated with disease activity. Multiple Sclerosis and Related Disorders, 2017, 13, 25-27.	0.9	13
64	Relationship between soluble CD25 and gene expression in healthy individuals and patients with multiple sclerosis. Cytokine, 2017, 93, 15-25.	1.4	12
65	MAIT cell subtypes in multiple sclerosis. Journal of Neuroimmunology, 2020, 339, 577117.	1.1	12
66	Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry. PLoS ONE, 2021, 16, e0250820.	1.1	12
67	Pregnancy-Induced Changes in microRNA Expression in Multiple Sclerosis. Frontiers in Immunology, 2020, 11, 552101.	2.2	12
68	Diagnostic Value of Oligoclonal Bands in Children: A Nationwide Population-Based Cohort Study. Pediatric Neurology, 2019, 97, 56-63.	1.0	11
69	Multiplex assessment of cerebrospinal fluid biomarkers in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 45, 102391.	0.9	11
70	Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS. BMC Medicine, 2020, 18, 298.	2.3	11
71	Pregnancy-Related and Perinatal Outcomes in Women With Multiple Sclerosis. Neurology: Clinical Practice, 2021, 11, 280-290.	0.8	11
72	Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry. Multiple Sclerosis Journal, 2021, 27, 2254-2266.	1.4	11

#	Article	IF	Citations
73	Natalizumab differentially affects plasmablasts and B cells in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 52, 102987.	0.9	11
74	Increased Intrathecal Activity of Follicular Helper T Cells in Patients With Relapsing-Remitting Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	11
75	Clinical utility of anti-MOG antibody testing in a Danish cohort. Multiple Sclerosis and Related Disorders, 2018, 26, 61-67.	0.9	10
76	Inflammatory markers of CHMP2B-mediated frontotemporal dementia. Journal of Neuroimmunology, 2018, 324, 136-142.	1.1	10
77	Prediction of natalizumab anti-drug antibodies persistency. Multiple Sclerosis Journal, 2019, 25, 392-398.	1.4	10
78	CSF proteome in multiple sclerosis subtypes related to brain lesion transcriptomes. Scientific Reports, 2021, 11, 4132.	1.6	10
79	Functional neuroimaging of recovery from motor conversion disorder: A case report. NeuroImage, 2019, 190, 269-274.	2.1	9
80	Brief international cognitive assessment for multiple sclerosis (BICAMS): A danish validation study of sensitivity in early stages of MS. Multiple Sclerosis and Related Disorders, 2020, 37, 101458.	0.9	9
81	Recovery from an acute relapse is associated with changes in motor resting-state connectivity in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 912-914.	0.9	8
82	Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 188-197.	1.4	8
83	Cladribine inhibits secretion of pro-inflammatory cytokines and phagocytosis in human monocyte-derived M1 macrophages in-vitro. International Immunopharmacology, 2021, 91, 107270.	1.7	8
84	The effectiveness of natalizumab vs fingolimodâ€“A comparison of international registry studies. Multiple Sclerosis and Related Disorders, 2021, 53, 103012.	0.9	8
85	Myelin Basic Protein-Induced Production of Tumor Necrosis Factor-Î± and Interleukin-6, and Presentation of the Immunodominant Peptide MBP85-99 by B Cells from Patients with Relapsing-Remitting Multiple Sclerosis. PLoS ONE, 2016, 11, e0146971.	1.1	8
86	Imaging cortical multiple sclerosis lesions with ultra-high field MRI. NeuroImage: Clinical, 2021, 32, 102847.	1.4	8
87	Ocrelizumab treatment in multiple sclerosis: A Danish populationâ€based cohort study. European Journal of Neurology, 2022, 29, 496-504.	1.7	8
88	Oligoclonal band phenotypes in MS differ in their HLA class II association, while specific KIR ligands at HLA class I show association to MS in general. Journal of Neuroimmunology, 2014, 274, 174-179.	1.1	7
89	Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 556-562.	0.9	7
90	Age and sex as determinants of treatment decisions in patients with relapsing-remitting MS. Multiple Sclerosis and Related Disorders, 2021, 50, 102813.	0.9	7

#	Article	IF	Citations
91	The Effect of Cannabis-Based Medicine on Neuropathic Pain and Spasticity in Patients with Multiple Sclerosis and Spinal Cord Injury: Study Protocol of a National Multicenter Double-Blinded, Placebo-Controlled Trial. Brain Sciences, 2021, 11, 1212.	1.1	7
92	Pregnancy in women with MS: Impact on long-term disability accrual in a nationwide Danish Cohort. Multiple Sclerosis Journal, 2022, 28, 1239-1247.	1.4	7
93	Preserved in vivo response to interferon-alpha in multiple sclerosis patients with neutralising antibodies against interferon-beta (REPAIR study). Multiple Sclerosis and Related Disorders, 2013, 2, 141-146.	0.9	6
94	Perfluorinated substances, risk factors for multiple sclerosis and cellular immune activation. Journal of Neuroimmunology, 2019, 330, 90-95.	1.1	6
95	IL2RA Methylation and Gene Expression in Relation to the Multiple Sclerosis-Associated Gene Variant rs2104286 and Soluble IL-2RÎ± in CD8+ T Cells. Frontiers in Immunology, 2021, 12, 676141.	2.2	6
96	Application of definitions for conversion to secondary progressive MS in a Danish nationwide population. Multiple Sclerosis and Related Disorders, 2021, 56, 103319.	0.9	6
97	Linking lesions in sensorimotor cortex to contralateral hand function in multiple sclerosis: a 7â€…T MRI study. Brain, 2022, 145, 3522-3535.	3.7	6
98	Serum neurofilament light chain in healthy elderly and in patients with ageâ€related macular degeneration. Acta Ophthalmologica, 2020, 98, e393-e394.	0.6	5
99	Motor fatigue is associated with asymmetric connectivity properties of the corticospinal tract in multiple sclerosis. NeuroImage: Clinical, 2020, 28, 102393.	1.4	5
100	Targeting B cells in multiple sclerosis. Current Opinion in Neurology, 2021, 34, 295-302.	1.8	5
101	Biomarkers of systemic inflammation, soluble IL-2RÎ± and the multiple sclerosis-associated IL2RA SNP rs2104286 in healthy subjects and multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2021, 54, 103140.	0.9	5
102	Charting a global research strategy for progressive MSâ€”An international progressive MS Alliance proposal. Multiple Sclerosis Journal, 2022, 28, 16-28.	1.4	5
103	Assessment of commonly used methods to determine myelin-reactivity of T cells in multiple sclerosis. Clinical Immunology, 2021, 230, 108817.	1.4	4
104	Smoking, cardiovascular risk factors and LRP2 gene variation: Associations with disease severity, cognitive function and brain structure in primary progressive multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 56, 103296.	0.9	4
105	Population-based head-to-head comparison of the clinical characteristics and epidemiology of AQP4 antibody-positive NMOSD between two European countries. Multiple Sclerosis and Related Disorders, 2021, 51, 102879.	0.9	3
106	The prognostic value of neurofilament light chain in serum. Lancet Neurology, The, 2022, 21, 207-208.	4.9	3
107	Neurofilament Light in Cerebrospinal Fluid is Associated With Disease Staging in European Lyme Neuroborreliosis. Journal of Central Nervous System Disease, 2022, 14, 117957352210981.	0.7	2
108	A clinically useful genetic variant in multiple sclerosis?. Nature Reviews Neurology, 2015, 11, 371-372.	4.9	1

#	Article	IF	Citations
109	Effectiveness of glatiramer acetate in neutralizing antibody-positive patients previously treated with interferon-Î². Multiple Sclerosis and Related Disorders, 2020, 39, 101894.	0.9	1
110	Transcriptome and Function of Novel Immunosuppressive Autoreactive Invariant Natural Killer T Cells That Are Absent in Progressive Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, e1065.	3.1	1
111	Interleukin-2 effect on T cell activation revealed by daclizumab treatment. Multiple Sclerosis and Related Disorders, 2012, 1, 8.	0.9	0
112	Author response: Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark. Neurology, 2019, 93, 723-723.	1.5	0
113	Methylprednisolone treatment, immune activation, and intrathecal inflammation in multiple sclerosis. Danish Medical Bulletin, 2004, 51, 167-83.	0.3	0